[1]任益功,吴敬玺,梁 业,等.经腹主动脉插管行肝癌模型大鼠肝动脉栓塞安全性和可行性研究[J].介入放射学杂志,2025,34(04):380-384.[doi:10.3969/j.issn.1008-794X.2025.04.007]
　REN Yigong,WU Jingxi,LIANG Ye,et al.Hepatic arterial embolization through abdominal aorta catheterization in rat liver cancer models:study of its safety and feasibility[J].J Intervent Med,2025,34(04):380-384.[doi:10.3969/j.issn.1008-794X.2025.04.007]
点击复制

经腹主动脉插管行肝癌模型大鼠肝动脉栓塞安全性和可行性研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年04
页码:
380-384
栏目:
实验研究
出版日期:
2025-04-23

文章信息/Info

Title:
Hepatic arterial embolization through abdominal aorta catheterization in rat liver cancer models:study of its safety and feasibility
文章编号:
1008-794X(2025)-004-0380-05
作者:
任益功;  吴敬玺;  梁 业;  袁 冰;  段 峰
100853 北京 解放军医学院(任益功、吴敬玺、梁 业); 解放军总医院第五医学中心肿瘤医学部(任益功、吴敬玺、梁 业、袁 冰、段 峰)
Author(s):
REN Yigong; WU Jingxi; LIANG Ye; YUAN Bing; DUAN Feng.
Chinese PLA Medical School,Beijing 100853,China
关键词:
动物实验;  介入放射学;  大鼠
分类号:
Q95-336
DOI:
10.3969/j.issn.1008-794X.2025.04.007
文献标志码:
A
摘要:
目的 探讨经腹主动脉插管行肝癌模型大鼠肝动脉栓塞术的安全性和可行性。方法 采用McA-Rh7777细胞原位种植法建立20只Sprague-Dawley 大鼠肝癌模型,随机分为A、B组,每组10只。A组经腹主动脉插管行肝动脉造影和栓塞,B组经胃十二指肠动脉逆行插管至肝固有动脉给药,行肝动脉造影和栓塞。记录A、B两组手术时间、手术成功率、术中及术后手术并发症。观察大鼠术后恢复情况。通过术前1 d与术后1、5、7 d 腹部CT平扫验证碘化油沉积情况。结果 A组、B组手术时间分别为(15.11±0.70)min、(34.39±1.60)min(P=0.036),手术成功率分别为100%、60%(P=0.043),差异均有统计学意义。两组均未发生明显手术并发症,手术成功大鼠术后CT平扫均可见肝脏碘化油沉积致密。结论 经腹主动脉插管行肝癌模型大鼠肝动脉栓塞术是一种安全可行的手术方法。

参考文献/References:

[1] Reig M,Forner A,Rimola J,et al.BCLC strategy for prognosis prediction and treatment recommendation:the 2022 update[J].J Hepatol,2022,76:681-693.
[2]Sun Y,Wu L,Zhong Y,et al.Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J].Cell,2021,184:404-421.e16.
[3]Chang X,Lu X,Guo J,et al.Interventional therapy combined with immune checkpoint inhibitors:Emerging opportunities for cancer treatment in the era of immunotherapy[J].Cancer Treat Rev,2019,74:49-60.
[4]管 阳,刘凤永,付金鑫,等.肝癌动物模型与介入实验操作应用[J].介入放射学杂志,2017,26:1046-1051.
[5]Li J,Wang X,Ren M,et al.Advances in experimental animal models of hepatocellular carcinoma[J].Cancer Med,2023,12:15261-15276.
[6]Cobaugh DJ,Chen TF,Frontini R,et al.Advancing responsible use of medicines globally:The revised Basel Statements[J].Am J Health Syst Pharm,2016,73:1027-1028.
[7]Groß C,Steiger K,Sayyed S,et al.Model matters:differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib[J].Clin Cancer Res,2015,21:4440-4450.
[8]Keller S,Chapiro J,Brangsch J,et al.Quantitative MRI for assessment of treatment outcomes in a rabbit VX2 hepatic tumor model[J].J Magn Reson Imaging,2020,52:668-685.
[9]Li M,Yin H,Yan Z,et al.The immune microenvironment in cartilage injury and repair[J].Acta Biomater,2022,140:23-42.
[10]Kidd JG,Rous P.A Transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form[J].J Exp Med,1940,71:813-838.
[11]许卫国,杨建勇,李鹤平,等.建立大鼠肝动脉插管途径的方法学研究[J].介入放射学杂志,2007,16:264-265.
[12]管 阳,刘凤永,樊庆胜,等.一种改良的大鼠胃十二指肠动脉逆行给药方法[J].介入放射学杂志,2018,27:349-352.
[13]Chandra VM,Wilkins LR,Brautigan DL.Animal models of hepatocellular carcinoma for local-regional intraarterial therapies[J].Radiol Imaging Cancer,2022,4:e210098.
[14]洪笑阳,刘键鑫,郭钊雄,等.经尾动脉入路原发性肝癌大鼠TACE模型的构建[J].介入放射学杂志,2023,32:1096-1100.
[15]Kumagai K,Horikawa M,Yamada K,et al.Transtail artery access in rats:a new technique for repeatable selective angiography[J].J Vasc Interv Radiol,2020,31:678-681.
(收稿日期:2024-10-06)
(本文编辑:谷 珂)

相似文献/References:

[1]许成钊,周祝谦,张经建,等.抗癌混悬乳剂微型电动制备机的研制及临床应用[J].介入放射学杂志,1992,(01):55.
[2]贾雨辰,王振堂,田建明,等.肝癌的介入放射学新进展[J].介入放射学杂志,1992,(01):52.
[3]章宏清,乔德林,王建国,等.中、小医院开展介入治疗的几点体会[J].介入放射学杂志,1992,(01):58.
[4].《林贵教授论文集》即将出版[J].介入放射学杂志,1992,(01):13.
[5]方心华,王淦森.应用国产XG500毫安X线机开展肿瘤介入性治疗的体会[J].介入放射学杂志,1993,(01):38.
[6]王执民.科学管理、促进介入放射学的发展[J].介入放射学杂志,1993,(01):58.
[7]朱琪,沈林祥,何炳轩,等.利用旋转坐椅施行经皮肺穿术[J].介入放射学杂志,1994,(01):17.
[8]金震东.介入性超声在消化系疾病的应用[J].介入放射学杂志,1994,(02):115.
[9]段孝敏.德国新产品-血管内支架置放术研讨会在沪召开[J].介入放射学杂志,1994,(02):64.
[10].《临床介入治疗学》出版[J].介入放射学杂志,1994,(03):142.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金面上项目(82172037)
通信作者: 段 峰 E-mail:duanfeng@vip.sina.com
更新日期/Last Update: 2025-04-25